(NASDAQ: CING) Cingulate's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 81.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Cingulate's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast CING's revenue for 2026 to be $33,747,081, with the lowest CING revenue forecast at $25,438,858, and the highest CING revenue forecast at $42,055,304. On average, 2 Wall Street analysts forecast CING's revenue for 2027 to be $82,053,849, with the lowest CING revenue forecast at $54,666,482, and the highest CING revenue forecast at $109,441,215.
In 2028, CING is forecast to generate $120,158,011 in revenue, with the lowest revenue forecast at $120,158,011 and the highest revenue forecast at $120,158,011.